Clinical Trial Update: Temsirolimus as Second-line Therapy in HCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating temsirolimus as second-line therapy for unresectable or metastatic hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Torisel (Temsirolimus)

Snippet

Sponsor: University of Tennessee Cancer Institute | Conditions: Unresectable or Metastatic Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN